默克医药公司肺癌晚期临床实验大幅提高存活及无癌症病兆率

来源: 2018-01-16 08:31:10 [旧帖] [给我悄悄话] 本文已被阅读:

Merck’s lung cancer treatment, Ketruda, performed better than expected in a late-stage, Phase 3 trial which has “significantly improved overall survival and progression-free survival”.